Inside the research

IDEXX Laboratories, Inc.

IDXX Research profile · latest available data

Price overview

$519.26

▲ +5.87 (+1.1%)

52w hi$766.68
52w lo$504.70
Vol331.10K
As of25 Sep 2026

The Verdict

Hold

Our score -0.40

Short-0.66
Medium-0.33
Long-0.02

computed 2026-09-27

Key fundamentals

IDEXX Laboratories, Inc.

Healthcare · Diagnostics & Research

Market cap$40.91B
Enterprise value$41.81B
Trailing P/E36.49x
Forward P/E31.02x
EV / EBITDA25.78x
P / S (ttm)9.00x
Profit margin25.0%
Return on equity74.2%
Revenue growth+9.7%
Earnings growth+17.6%
Debt / equity67.97

Layer Breakdown

LayerRawContribution
Fundamental+0.21
Sector+0.08
Technical-0.47
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

United States · www.idexx.com

Risk Metrics

Beta vs SPX0.96
Corr SPX0.41
Annual vol37.6%
Annual ret+7.9%
Sharpe0.21
Max DD-34.2%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$709.14
High / Low$805.00 / $470.00
Median$712.50
Analysts14
Strong Buy4
Buy5
Hold5
Sell0
Strong Sell1

Recent rating actions

2026-04-28UBS→ Neutral
2026-04-15Citigroup→ Neutral
2026-03-31Stifel→ Buy
2026-02-09Piper Sandler→ Neutral
2026-02-05Barclays→ Overweight
2026-02-03UBS→ Neutral

Material Events

DateEvent8-K
2026-08-04Earnings Release, Exhibitsread
2026-05-15Bylaws Amendment, Shareholder Vote…read
2026-05-05Earnings Release, Exhibitsread
2026-03-26Officer / Director Change, Exhibitsread
2026-02-13Officer / Director Changeread
2026-02-02Earnings Release, Exhibitsread
2026-01-13Officer / Director Change, Reg FD Disclosure…read
2025-11-13Material Agreement, Material Obligation…read
2025-11-03Earnings Release, Exhibitsread
2025-10-07Officer / Director Change, Exhibitsread
2025-08-04Earnings Release, Exhibitsread
2025-07-10Officer / Director Change, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-07-30HOOLEY JOSEPH LGrant49$27.38K
2026-06-01FENNELL GEORGEExecutive Vice PresidentOption exercise639—
2026-06-01FENNELL GEORGEExecutive Vice PresidentWithheld for tax284$160.97K

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders0
Top-5 share0.0%
HHI0 (—)

SEC Filings

DateFormDoc
2026-08-048-Kview
2026-08-0410-Qview
2026-08-034view
2026-06-024view
2026-05-158-Kview
2026-05-144view
2026-05-144view
2026-05-144view
2026-05-144view
2026-05-144view
2026-05-144view
2026-05-144view
2026-05-144view
2026-05-144view
2026-05-114view

The Long Run

FY 2010–2025 · 16 years

LineLatestCAGRTrend
Revenue$4.30B+10.0%
Gross profit$2.38B+10.5%
Operating income$1.36B+14.8%
Net income$1.06B+15.9%
Cash from ops$1.18B+17.0%

Indices

NASDAQ-100S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$510.94$520.16$507.01$519.26331.10K
Sep 24$520.88$524.12$511.73$513.39328.30K
Sep 23$517.20$523.22$516.88$522.02364.20K
Sep 22$519.27$523.95$511.73$521.50476.50K
Sep 21$511.65$518.96$506.22$515.30513.20K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →